Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X **ao, S Huang, S Chen, Y Wang, Q Sun… - Journal of Experimental & …, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
Next generations of CAR-T cells-new therapeutic opportunities in hematology?
J Tomasik, M Jasiński, GW Basak - Frontiers in Immunology, 2022 - frontiersin.org
In recent years, the introduction of chimeric antigen receptor (CAR) T-cell therapies into
clinics has been a breakthrough in treating relapsed or refractory malignancies in …
clinics has been a breakthrough in treating relapsed or refractory malignancies in …
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
X Hu, K Manner, R DeJesus, K White, C Gattis… - Nature …, 2023 - nature.com
Manufacturing autologous chimeric antigen receptor (CAR) T cell therapeutics is complex,
and many patients experience treatment delays or cannot be treated at all. Although current …
and many patients experience treatment delays or cannot be treated at all. Although current …
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
L Lu, M **e, B Yang, W Zhao, J Cao - Science Advances, 2024 - science.org
Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …
therapy for cancer that has demonstrated notable potential in clinical applications. However …
CAR T cells: Building on the CD19 paradigm
A Globerson Levin, I Rivière, Z Eshhar… - European journal of …, 2021 - Wiley Online Library
Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19,
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …
Genetically engineered hypoimmunogenic cell therapy
Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …
transplantation into immunocompetent patients. Genetic modification has emerged as a …
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
X Gu, Y Zhang, W Zhou, F Wang, F Yan, H Gao… - … Hematology & Oncology, 2024 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has achieved substantial clinical outcomes
for tumors, especially for hematological malignancies. However, extending the duration of …
for tumors, especially for hematological malignancies. However, extending the duration of …
Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective
X Si, T Gu, L Liu, Y Huang, Y Han, P Qian, H Huang - Cancer Letters, 2022 - Elsevier
Abstract Chimeric Antigen-Receptor (CAR) T-cell therapies have shown dramatic efficacy in
treating relapsed and refractory cancers, especially B cell malignancies. However, these …
treating relapsed and refractory cancers, especially B cell malignancies. However, these …